US FDA warns Mylan over quality at Telangana plant

Hyderabad, Sep 3 (IANS) The US Food and Drug Administration has issued a warning letter to global pharma major Mylan Laboratories Ltd for significant deviations from Current Good Manufacturing Practices (CGMP) for making active pharmaceutical ingredients (APIs) at its plant in Telangana.

Hyderabad, Sep 3 (IANS) The US Food and Drug Administration has issued a warning letter to global pharma major Mylan Laboratories Ltd for significant deviations from Current Good Manufacturing Practices (CGMP) for making active pharmaceutical ingredients (APIs) at its plant in Telangana.

The drug regulator expressed concerns about Mylan’s lack of cleaning records and inadequate quality control for certain manufacturing and storage equipment at its Unit 7 at Pashamylaram, Patancheru in Sangareddy district.

The FDA alleged in its letter dated September 1 that Mylan did not do a sufficient job testing all incoming raw materials to ensure they are suitable for the manufacturing process and didn’t have adequate procedures for detecting impurities. It observed that this coupled with using non-dedicated equipment, created the risk of contaminating the ingredients that go into Mylan’s medicines.

The federal agency stated that its investigators during the inspections of the facility between February 24 and 28 this year found lapses in the plant as there were no adequate cleaning procedures to prevent contamination or carry-over of a material that would alter the quality of the API.

“In addition to your lack of cleaning records, your cleaning validation and verification programme for non-dedicated manufacturing and storage equipment are inadequate,” the FDA said.

This is the second warning letter by FDA to Mylan for similar issues in less than a year. The drug-maker was issued a warning letter in November last year for another unit in Andhra Pradesh.

The warning was issued for Unit 8 for failure to have adequate written procedures for receipt, identification, testing, and handling of raw materials and a failure to clean equipment and utensils to prevent contamination or carry-over of material.

“We observed similar deficiencies related to inadequate storage and handling of recovered solvents utilised at your Unit 7 API manufacturing operations. These repeated failures at multiple sites manufacturing API demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements at all your sites,” reads the FDA letter.

“Until you correct all deviations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer,” it added.

Mylan, however, said it does not anticipate any interruption in manufacturing and distribution at the site.

“The US Food and Drug Administration (FDA) issued a Warning Letter to Mylan’s API manufacturer, Mylan Laboratories Ltd – Unit 7, in which no interruption in manufacturing and distribution is anticipated at the site, no significant commercial impact is expected and no significant launches are planned for Unit 7 in 2020,” Mylan said in a statement.

It said several months prior to the inspection, it put additional controls, corrective actions and improvements in place at the facility to mitigate any perceived risk of product contamination with patient safety as its primary focus.

“Importantly, extensive testing of APIs manufactured and distributed by the site was performed for the presence of nitrosamine impurities and no evidence of cross contamination was identified,” said Mylan which is incorporated in the Netherlands but has corporate headquarters in the US.

Mylan said it will submit its response to the letter within the required time period of 15 working days.

“Mylan is committed to maintaining the highest quality manufacturing standards at all of its facilities around the world. We have an industry-leading track record in global quality management, and we take very seriously our continued and comprehensive oversight of Mylan’s entire manufacturing network,” it added.

–IANS

ms/vd

ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.